360 related articles for article (PubMed ID: 22344548)
1. The pharmacological profile and clinical use of mesalazine (5-aminosalicylic acid).
Klotz U
Arzneimittelforschung; 2012 Feb; 62(2):53-8. PubMed ID: 22344548
[TBL] [Abstract][Full Text] [Related]
2. Drug insight: aminosalicylates for the treatment of IBD.
Nielsen OH; Munck LK
Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853
[TBL] [Abstract][Full Text] [Related]
3. Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis.
Harris MS; Lichtenstein GR
Aliment Pharmacol Ther; 2011 May; 33(9):996-1009. PubMed ID: 21385194
[TBL] [Abstract][Full Text] [Related]
4. Mesalazine for the treatment of inflammatory bowel disease.
Criscuoli V; Modesto I; Orlando A; Cottone M
Expert Opin Pharmacother; 2013 Aug; 14(12):1669-78. PubMed ID: 23767798
[TBL] [Abstract][Full Text] [Related]
5. The metabolism of mesalamine and its possible use in colonic diverticulitis as an anti-inflammatory agent.
Cohen HD; Das KM
J Clin Gastroenterol; 2006 Aug; 40 Suppl 3():S150-4. PubMed ID: 16885699
[TBL] [Abstract][Full Text] [Related]
6. Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties.
Tromm A; Griga T; May B
Hepatogastroenterology; 1999; 46(30):3124-35. PubMed ID: 10626173
[TBL] [Abstract][Full Text] [Related]
7. Encapsulated mesalamine granules (Apriso) for ulcerative colitis.
Med Lett Drugs Ther; 2009 May; 51(1312):38-9. PubMed ID: 19448588
[TBL] [Abstract][Full Text] [Related]
8. Controversies with aminosalicylates in inflammatory bowel disease.
Lim WC; Hanauer SB
Rev Gastroenterol Disord; 2004; 4(3):104-17. PubMed ID: 15359211
[TBL] [Abstract][Full Text] [Related]
9. 5-Aminosalicylic acid derivatives. Clinical and pharmaceutical evaluation.
Christensen LA; Jacobsen BA
Neth J Med; 1989 Jun; 35 Suppl 1():S3-10. PubMed ID: 2702310
[TBL] [Abstract][Full Text] [Related]
10. [5-aminosalicylic acid in the treatment of ulcerative colitis and Crohn's disease].
Moum B
Tidsskr Nor Laegeforen; 2003 Sep; 123(18):2565-7. PubMed ID: 14714043
[TBL] [Abstract][Full Text] [Related]
11. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study.
Bernstein CN; Nugent Z; Blanchard JF
Am J Gastroenterol; 2011 Apr; 106(4):731-6. PubMed ID: 21407180
[TBL] [Abstract][Full Text] [Related]
12. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.
Lichtenstein GR; Kamm MA; Sandborn WJ; Lyne A; Joseph RE
Aliment Pharmacol Ther; 2008 Jun; 27(11):1094-102. PubMed ID: 18363894
[TBL] [Abstract][Full Text] [Related]
13. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis.
Marshall JK; Irvine EJ
Am J Gastroenterol; 2000 Jul; 95(7):1628-36. PubMed ID: 10925961
[TBL] [Abstract][Full Text] [Related]
14. Multiparticulate systems containing 5-aminosalicylic acid for the treatment of inflammatory bowel disease.
Bautzová T; Rabišková M; Lamprecht A
Drug Dev Ind Pharm; 2011 Sep; 37(9):1100-9. PubMed ID: 21417610
[TBL] [Abstract][Full Text] [Related]
15. Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease.
Mulder CJ; van den Hazel SJ
Mediators Inflamm; 1998; 7(3):135-6. PubMed ID: 9705596
[TBL] [Abstract][Full Text] [Related]
16. Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease.
Klotz U; Schwab M
Adv Drug Deliv Rev; 2005 Jan; 57(2):267-79. PubMed ID: 15555742
[TBL] [Abstract][Full Text] [Related]
17. 5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man.
Christensen LA
Dan Med Bull; 2000 Feb; 47(1):20-41. PubMed ID: 10709142
[TBL] [Abstract][Full Text] [Related]
18. Inducing and maintaining remission in ulcerative colitis: role of high-dose, extended-release mesalamine.
Kao J; Kwok K; Das KM
J Clin Gastroenterol; 2010 Sep; 44(8):531-5. PubMed ID: 20495466
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse.
Ritland SR; Leighton JA; Hirsch RE; Morrow JD; Weaver AL; Gendler SJ
Clin Cancer Res; 1999 Apr; 5(4):855-63. PubMed ID: 10213222
[TBL] [Abstract][Full Text] [Related]
20. Will a 5-ASA a day keep the cancer (and dysplasia) away?
Rubin DT; Lashner BA
Am J Gastroenterol; 2005 Jun; 100(6):1354-6. PubMed ID: 15929769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
